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Abstract
In omic research, such as genome wide association studies, researchers seek to
repeat their results in other datasets to reduce false positive findings and thus
provide evidence for the existence of true associations. Unfortunately this standard
validation approach cannot completely eliminate false positive conclusions, and it
can also mask many true associations that might otherwise advance our
understanding of pathology. These issues beg the question: How can we increase
the amount of knowledge gained from high throughput genetic data? To address
this challenge, we present an approach that complements standard statistical
validation methods by drawing attention to both potential false negative and false
positive conclusions, as well as providing broad information for directing future
research. The Diverse Convergent Evidence approach (DiCE) we propose integrates
information from multiple sources (omics, informatics, and laboratory experiments) to
estimate the strength of the available corroborating evidence supporting a given
association. This process is designed to yield an evidence metric that has utility
when etiologic heterogeneity, variable risk factor frequencies, and a variety of
observational data imperfections might lead to false conclusions. We provide proof
of principle examples in which DiCE identified strong evidence for associations that
have established biological importance, when standard validation methods alone did
not provide support. If used as an adjunct to standard validation methods this
approach can leverage multiple distinct data types to improve genetic risk factor
discovery/validation, promote effective science communication, and guide future
research directions.
Keywords: Replication, Validation, Complex disease, Heterogeneity, GWAS, Omics,
Type 2 error, Type 1 error, False negatives, False positives
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Introduction
The validation of findings in complex disease research
The accepted gold standard for demonstrating associations in omic research settings,
such as genome wide association studies, is the independent replication of preliminary
findings [1]. Testing for replication involves assessing consistency by trying to repeat
results in an independent sample from the original population with the same analytic
approach [2]. However, many large genetic epidemiology studies and meta-analyses do
not use samples from one source population, and therefore, do not attempt replication
per se, but validation [2]. This conventional confirmation process can help to minimize
false positive findings, and in doing so provides fairly compelling evidence for the exist-
ence of true associations. Although in recent years it has become evident that chance,
limited power, publication bias and a variety of other factors can make this evidence
less compelling than it otherwise would be [3,4]. Unfortunately, this methodology can
also mask many true associations that would otherwise advance etiological research.
Given that the efficacy and efficiency of research depends on reducing both false posi-
tive and false negative conclusions, validation approaches should be developed that can
better prevent both types of erroneous conclusions.
If our goal is to find factors, such as genetic or environmental factors that contribute
to pathophysiology, then we need to consider whether using standard validation meth-
odology alone provides the best approach. In this paper, we propose an additional val-
idation framework that can be used to enhance discovery and validation in omic
research settings, such as transcriptome, exposome, and genome-wide association
studies (GWAS).
Shortcomings of traditional validation
Contemporary validation methods require that disease associations are observable in mul-
tiple study populations. If we acknowledge the heterogeneity of complex disease and the
limitations of observational data, then we should expect that many biologically meaning-
ful associations will not be consistently confirmed by these standard validation methods.
The etiologies of complex diseases may involve multiple causal cofactors, and each of
these factors may have distributions that vary greatly between study populations. We also
know that observational data is often flawed; crucial variables may be unmeasured or in-
consistently measured, and systematic biases can occur in ascertainment, measurement,
study design, and analysis. Thus, there are numerous situations in which a true finding
may fail to be confirmed using the traditional validation approach [5-7].
Additionally, current validation methods may unnecessarily inflate the rate of false
negative conclusions by requiring strict multiple testing adjustments in settings where
false positive conclusions could be effectively minimized with additional confirmatory
data [8]. In other words, a single p-value threshold in a single analysis, no matter how
strict the adjustment for multiple testing, may do a poor job of distinguishing true posi-
tive findings. Zaykin and Zhivotovsky [9] point out that the p-values for true associa-
tions tend to have ranks that are interspersed among p-values for false positive findings
and that these true association p-values are often not found among the most extreme
values. Thus, even strict significance thresholds cannot always separate true positive
from false positive findings, and more evidence will generally be needed to determine
which associations are worthy of follow-up. Multiple testing corrections can reduce
Ciesielski et al. BioData Mining 2014, 7:10 Page 2 of 17
http://www.biodatamining.org/content/7/1/10
type 1 errors, but they cannot solve the primary problem, that a single threshold in one
analysis cannot distinguish between noise and signal of the same magnitude.
Finally, even when a finding is robust and traditional validation is observed, it still
might be a false positive [7], and a consistent pattern of bias may explain the results.
Careful validation protocols within one type of data should reduce false positive find-
ings [10] but they cannot prevent false positive findings due to cryptic bias that is in-
trinsic to that single data type (e.g. consistent confounding in the relevant observational
studies that is consistently not accounted for). In other words traditionally-validated find-
ings that have not been examined with diverse methods may still be spurious because
of systematic errors present in the single research approach used. Overall, we know
that p-values have a variety of weaknesses when being used in scientific reasoning
[11,12], and we should recognize these limitations by reinforcing our frameworks for
discovery and validation.
Proposed: a new approach that utilizes Diverse Convergent Evidence (DiCE)
We argue that the conventional procedures for risk factor validation could be enhanced
with the addition of a supplementary method that systematically assesses diverse inde-
pendent lines of evidence. This type of multifaceted strategy could provide useful informa-
tion in the presence of causal heterogeneity, unrecognized bias, imperfect study designs
and other settings where traditional omic validation may yield erroneous conclusions. In
this approach researchers actively gather multiple distinct sources of evidence to assess a
given factor (e.g., variant, gene, exposure, or pathway) in the pathophysiology of interest.
Then multiple findings from various research fields can be combined to gauge whether a
critical mass of evidence implicates a given factor. In this process the weaknesses of one
methodology can be addressed by the complementary strengths of others; for example,
evidence from knockout animal models can support information from genetic epidemi-
ology, and findings from experimental toxicology can strengthen information from envir-
onmental epidemiology.
Here we propose a framework, Diverse Convergent Evidence (DiCE), that can help
researchers to assess the importance of potential factors and decide how to proceed
(Figure 1). DiCE promotes the coordination of complementary information from dis-
tinct fields to guide decisions about which findings are most worthy of follow-up ef-
forts. When considered with the results of standard validation procedures DiCE can be
used to highlight conclusions that may be erroneous (false negative or false positive)
based on a systematic assessment of external knowledge. In its role as a complementary
methodology DiCE does not propose a definitive endpoint or establish a single criterion
for association. Rather, it distinguishes between strong and weak evidence with the in-
tent of guiding subsequent research. This approach reflects the long-known, but rarely
utilized perspective that scientific reasoning can provide guidelines but not rigid criteria
for causal inference [13,14]. Typically, no single piece of evidence is necessary or suffi-
cient for causal inference in complex disease research. If applied appropriately, the con-
sideration of diverse lines of evidence can clarify what additional information is needed
to advance our understanding of a given disease process and help investigators to apply
limited resources intelligently. This framework moves beyond a single narrow approach
for answering questions about complex disease to appropriately reflect etiologic and
inter-dataset heterogeneity when seeking causative factors.
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Integrating evidence to calculate a DiCE score
The DiCE system evaluates putative causal factors (e.g. genes or environmental exposures)
in three broad categories of evidence: omic/observational, informatic, and laboratory ex-
periments (Figure 1). As proposed, evidence from each category contributes to a compos-
ite score that reflects the overall strength of the evidence for a factor’s involvement in the
pathophysiology of interest (Table 1 and Figure 2). The score for a given factor is ele-
vated in the presence of diverse convergent evidence. This approach can help researchers
to: 1) characterize the available evidence for a specific factor of interest; and 2) prioritize
findings for further research.
Omic evidence
In this framework a factor receives 1 point for being identified in an omic screening
analysis (e.g. GWAS) and can then receive 3 additional points if it is validated in a sec-
ond omic study using standard methods. The choice of a significance threshold is a
hotly debated topic in the setting of agnostic omic scans. Because a number of signifi-
cance thresholds can be defended, we leave this to the discretion of the researcher, as
long as a consistent rationale is used. In our examples, we use the commonly accepted
multiple testing adjusted significance threshold of p < 5 × 10−8 [15]. To account for
Figure 1 Scoring system concept for prioritizing research findings in complex disease research.
Heat Map image adapted from [47]. Manhattan Plot image adapted from [48]. PubMed image adapted
from the PubMed database website (http://www.ncbi.nlm.nih.gov/pubmed [16]) after typing in “ppar
gamma” (as seen on June 9, 2014). Pathway/network image adapted from [49]. Microscopy images adapted
from [50]. Mouse images adapted from [51]. Underlying images adapted from [47-51] were published under
the creative commons attribution license which allows for re-use without permission (http://www.plosone.
org/static/license http://creativecommons.org/licenses/by/3.0/ http://creativecommons.org/licenses/by/3.0/
legalcode).
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some of the causes of type II error in standard omic validation attempts, a risk factor
that does not receive the initial 3 standard validation points can still obtain 2 points for
validation through alternative exploratory approaches. Some examples of defensible al-
ternative statistical validation attempts would include: validation by meta-analysis;
validation using a distinct analytic method (e.g. PCA adjusted vs. not, using imputation
vs. not etc.); or validation after accounting for a masking covariate in your analysis (e.g.
stratifying or adjusting for a confounder, or considering an interacting variable). The
lower point value assigned to alternative statistical validation reflects the lower quality
of evidence obtained through these post hoc validation attempts.
Figure 2 Hypothetical DiCE scoring system implementation. Underlying Manhattan Plot image adapted
from [48]. The underlying image adapted from [48] was published under the creative commons attribution
license which allows for re-use without permission (http://www.plosone.org/static/license
http://creativecommons.org/licenses/by/3.0/ http://creativecommons.org/licenses/by/3.0/legalcode).
Table 1 Diverse Convergent Evidence (DiCE) point system concept
Omic/Observational evidence Biological database (Informatic)
evidence
Experimental (Laboratory) evidence
Single Significant Finding Evidence from PubMed, KEGG, GEO,
GO or etc. linking the factor to
the pathophysiology
Evidence from animal or cell/molecular
models demonstrating a role of the
factor in the pathophysiology
Yes (1 point) Yes (3 points) Yes (3 points)
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Biological database or informatic evidence
To incorporate biological database evidence, a factor can receive 3 points if supportive
evidence is obtained through informatics approaches. This is a broad category that en-
compasses evidence obtained from biological database (pathway or network analyses)
and literature searches. There are a number of approaches that could be used here, in-
cluding systematic searches in PubMed [16], GEO [17], or other NCBI interfaces [18],
as well as KEGG [19], GO [20], or other databases with biological annotations. Again,
as with the omic evidence, the specific type of search employed here is flexible, but it
should be kept consistent to generate comparable results.
Experimental evidence
Laboratory based information is integrated into the total score by adding 3 points if
there are experiments that support the involvement of this factor in the pathophysi-
ology of interest. These experiments may include animal knockout models, cell trans-
fections, and treatment with environmental risk factors such as nutrients, medicines,
or chemicals.
Some data may fit into more than one of the three categories but a single result
should only be counted once. Essentially, this process uses the sum of provisional nu-
merical values from distinct categories of evidence to evaluate the likelihood of a given
finding being true and worthy of subsequent study. We suggest that a total composite
score of ≥ 6 indicates strong evidence. Although the scores themselves are arbitrary,
they convey ordinal information about the available diverse evidence, and there is a
strong rationale for the relationship between the component scores and the chosen
threshold. No single category of evidence is necessary or sufficient to achieve a score
of 6. This threshold requires convergent evidence from at least two categories, but
protects the conclusion from being deleteriously affected if one category of evidence
(out of the three) is missing or flawed. Overall the DiCE process yields a semi-formal
dynamic heuristic that is based in logic and empiricism. The choice of search strat-
egies for implementing the DiCE framework can vary, but a thoughtful implementa-
tion combined with an explicit description of the search details, should consistently
yield useful information.
In this method the points are assigned such that roughly equal weight is given to the
three categories of validation evidence (omic, informatic, and experimental). This is de-
signed into our proposal because it is typically not appropriate to definitively pick one
category a priori as providing better evidence. For example, information from con-
trolled experiments may be worth more when a good and relevant disease model is
available. However, there may be no appropriate assays or models available for labora-
tory work or the available models may not be relevant to human physiology. The situ-
ation is even worse if the research community thinks they have a pertinent disease
model, but is unaware of its fundamental failings. Observational omic data that comes
from humans most likely has relevance to human disease. However, issues such as
measurement error and confounding may make observational data problematic, and it
is not always clear when these complications are present and unaccounted for. Having
approximately equal weights for the three evidence categories makes the total score
relatively resilient to the known and unknown failings of each type of evidence and pro-
vides no systematic and clear bias in score assignment.
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One could consider developing a more nuanced DiCE scoring rubric, by attempting
to quantify the number of total validations or rate of validation successes within each
evidence category. However, this approach could defeat the purpose of the method.
The number of validations within one category and the validation rate within each cat-
egory do not always have a clear and consistent relationship to the truth of the finding
in question, and we propose that at this point they should not be folded into the rubric
because of added ambiguity. These issues could be reconsidered for future modifica-
tions to the DiCE system.
Overall, DiCE is a dynamic heuristic approach that promotes the collection and inte-
gration of diverse evidence for scientific decision making. The DiCE score and the
follow-up directions it suggests can change as the available evidence changes.
Utility of the DiCE supplementary validation approach: empirical cases
Genetic resistance to severe malaria
In 2009 Jallow et al. published the results of a case control GWAS that searched for
genetic variants associated with resistance to severe malaria [21]. This study is of inter-
est because at the time of publication there were several previously established genetic
variants that were known to confer malaria resistance, including the Hemoglobin S al-
lele, which reduces the risk of severe malaria ten-fold. However, the Hemoglobin S sig-
nal (i.e. p-value for a marker SNP) did not achieve genome-wide significance at the
5 × 10−8 level [15] and none of the other known genetic risk factors (e.g., G6PD) met
this criterion. The authors discussed several reasons for the failure to identify known
loci, including low LD between the marker SNPs and the causal variants in their popu-
lations, and low frequencies of the causal variants in their populations. They were,
however, able to attain significance by fine mapping at the Hemoglobin S locus, which
was already known to associate with malaria from prior diverse evidence.
This highlights the importance of using more than one approach for causal factor iden-
tification, as information from independent lines of evidence prevented this variant from
being overlooked even though it was missed by GWAS. The DiCE validation strategy pro-
actively supports the collection of multifaceted evidence so that important signals are not
missed due to the flaws of a single study, criterion, or method. Here we use the search for
malaria resistance genes to demonstrate how our approach can help to characterize the
strength of available evidence for specific factors and clarify future research directions.
Hemoglobin S and malaria resistance
Using the DiCE scoring system we find that the evidence for the involvement of
Hemoglobin S in malaria resistance is strong (Table 2), with a total score of 9, even
though it failed traditional significance thresholds for genome wide association in the
initial GWAS. The implementation details for these analyses are provided in Additional
file 1. Other analytic choices could be utilized but a consistent approach should be ap-
plied throughout the implementation.
We argue that a score of 9 provides extremely strong evidence, only possible in the
presence of multiple convergent lines of evidence. In this case, we can definitively say
that adherence to a single conservative analytic approach would have obscured a find-
ing of biological interest. Rather than dismissing alternative omic analytic strategies,
this system simply adjusts the score to reflect the reduced quality of statistical evidence
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that comes from non-traditional exploratory approaches. This example serves as a
proof of principle for the DiCE approach and it also demonstrates that method can
highlight reasonable directions for future research (see Additional file 1).
ATP2B4, MARVELD3, and malaria resistance
A GWAS by Timmann et al. reported the putative association of two new genes with
malaria resistance. Several SNPs were detected within the ATP2B4 gene (encodes the
primary erythrocyte calcium pump) and one SNP was identified in an intergenic region
near MARVELD3 (encodes a tight junction associated protein in vascular endothelium)
[22]. Here we apply our method to these new findings to prioritize them for follow-up
(see Additional file 1).
ATP2B4 accrued an extremely strong score of 9 using our method (Table 2). Here
again alternative statistical validation methods proved useful in helping to prevent an
interesting lead from being overlooked. Our method also highlighted some of the next
research questions related to ATP2B4 (see Additional file 1).
The evidence summary for MARVELD3 was much less compelling with a score of 1
(Table 2). The weakness of the evidence for MARVELD3 at this point reflects that there
is a current dearth of research on MARVELD3 available to corroborate this finding,
and this leaves open the possibility that the SNP may be a false positive finding. How-
ever in this case, a weak DiCE score also suggests another possibility: that this SNP
may be linked to malaria resistance through a mechanism that does not involve MAR-
VELD3. Given that the SNP is near but not in MARVELD3, the function of this SNP in
malaria resistance (if it has one) may not involve MARVELD3. An exploration of other
nearby genes and any known regulatory functions of this region may be fruitful in help-
ing to identify another factor for DiCE to validate with respect to this SNP. In fact,
Timmann et al. notes that the identified SNP (rs2334880) is in an intergenic region be-
tween MARVELD3 and TAT (tyrosine aminotransferase) which are in a head-to-head
configuration. An NCBI search [18] for “tyrosine aminotransferase and malaria” identi-
fies a paper that implicates this enzyme in malaria pathophysiology [23] (yielding a
DiCE Score of 4 for tyrosine aminotransferase). Thus perhaps it is tyrosine aminotrans-
ferase that explains the association with this SNP, and this lead may be worthy of
follow-up. As always it is a judgment call, but unless more observational evidence
makes MARVELD3 more interesting, pursuing laboratory experiments for this gene is
Table 2 Results of implementing the DiCE evidence scoring system in four contexts











Hemoglobin S and malaria resistance
(a positive control that would not be
detected with traditional methods)
1 2 3 3 9
ATP2B4 and malaria resistance (new lead) 1 2 3 3 9
MARVELD3 and malaria resistance (new lead) 1 0 0 0 1
PPARγ and type 2 diabetes (another positive
control that would not be detected with
traditional methods)
0 0 3 3 6
*a total score of 6–10 is considered strong evidence.
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probably not warranted at this time. Importantly DiCE implementation has helped us
to think systematically about the available data and it can point to next steps even
when it does not point to strong conclusions.
We would argue that Timman et al. alone does not provide compelling evidence for
the involvement of either ATP2B4 or MARVELD3 in the pathogenesis of severe mal-
aria. Importantly, taking a single validation approach in this case does not allow these
leads to be distinguished. If one only considered the p-values, these leads would be al-
most impossible to differentiate in terms of their relative likelihood of being etiologic-
ally relevant, because the p-values for the SNPs in ATP2B4 (6.1 × 10−9, 1.5 × 10−8,
2.1 × 10−8, 5.1 × 10−8, 3.4 × 10−8) and the SNP near MARVELD3 (3.9 × 10−8) are very
similar. However, our simple process quickly characterized these two new leads and
revealed which is currently more worthy of follow-up based on the available diverse
evidence. The evidence for ATP2B4 is strong and suggests specific new laboratory ex-
periments, but the evidence for MARVELD3 is weak, and therefore provides less motiv-
ation for follow-up efforts at this point. The strong performance of our method in the
context of a very well established predictor of malaria resistance, Hemoglobin S, serves
as a positive control (method validation), and this further suggests that the conclusions
about ATP2B4 and MARVELD3 should be useful.
As we pointed out earlier the diverse evidence for MARVELD3 may be weak because
it has not been collected; we do not have much evidence for what we have not expli-
citly studied. Thus, in this case DiCE cannot provide strong evidence either way, and
this is appropriate, as we would argue that strong evidence does not exist in the ab-
sence of diverse validation. However, its implementation has suggested future steps:
1) explore potential functions of this SNP that do not involve MARVELD3 (there is evi-
dence that tyrosine aminotransferase may explain the association between malaria and
this SNP [23]), or 2) see if MARVELD3 is detected in the next genomic screen for mal-
aria resistance. The low DiCE score would indicate for most researchers that MAR-
VELD3 is not worthy of immediate laboratory follow-up. However, a researcher who
already has a well characterized vascular endothelium model in their laboratory may
find it worthwhile to make a MARVELD3 knockout without additional evidence, simply
because the activation energy is low for them. For other researchers, additional omic
validation and some informatic evidence would likely be required to make this finding
worthy of laboratory investigations.
PPARγ and type 2 diabetes
Traditional validation has also proven to have limitations in type 2 diabetes research. In
2007 Williams et al. [24] noted that the well-established target of an entire class of type
2 diabetes drugs (PPARγ [25]) would not have been identified de novo by 3 GWA stud-
ies published that year [26-28] if traditional methods of GWAS validation were rigidly
followed. The p-values for rs1801282 in the three studies were 0.019, 0.0013, and
0.0014, none of which coming close to traditional genome wide significance levels (in
fact, in one of the discovery scans the index SNP had a p value of 0.83). However, the
ORs were consistent (1.09 [95% CI: 1.01-1.16], 1.23 [95% CI: 1.09-1.41], 1.20 [95% CI:
1.07-1.33]), and a meta-analysis of the three studies, most likely pursued because the
PPARγ locus was already known based on non-GWAS-based evidence [25], yielded a
small p-value, though it was still not genome wide significant (p = 1.7 × 10−6). In other
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words, an enormous amount of expensive GWAS research would not have led us to
this type 2 diabetes drug target without some augmentation of traditional validation
processes. However, if we apply DiCE, the method correctly characterizes the evidence
for the biological relevance of PPARγ as strong.
Evidence for PPARγ in type 2 diabetes achieved a score of 6 (Table 2 and Additional
file 1). A score of 6 is strong evidence for the involvement of PPARγ, and because we
already know its importance in type 2 diabetes therapy, this example serves to validate
DiCE. Here we again demonstrate that adding the DiCE validation framework can allow
for the detection biologically important signals where standard approaches to validation
fail. The example of PPARγ in type 2 diabetes also illustrates that it may be worthwhile
to gather additional evidence on all hits with a p-value < 0.05 (or even p < 0.1). Further-
more, there is published evidence from the International Multiple Sclerosis Genetics
Consortium which demonstrates that this type of comprehensive validation effort can
be very fruitful [29]. If one is interested in filtering a large list of nominally significant
findings (p < 0.05) to identify a subset most worthy of follow-up, instead of characteriz-
ing the evidence for a single finding, our flexible scoring system can be utilized in this
setting as well. There will be many hits to follow-up for most complex diseases, but
these efforts should be worthwhile because DiCE allows us to better interpret omic
data in light of other biologically relevant signals.
Discussion
In this paper we have proposed a supplemental analytic framework (DiCE) to improve
discovery and validation performance in omic research settings such as GWAS. This
method promotes the collection of diverse evidence in order to leverage its inherent re-
sistance to the systematic failings that are possible with single approaches. Additionally it
allows for the coordination of varied evidence to effectively guide future research. We
have also illustrated the validity and utility of the DiCE strategy using four case studies:
two proof of principle examples and two exploratory examples. The proposed scoring sys-
tem is subjective, as is a nominal p of 0.05, but it accomplishes the major goal of combin-
ing multiple data types into a unified framework for evidence assessment.
R.A. Fisher, the father of p-value based inference, provides us with evidence that the
application of a thoughtful yet subjective convention can be very productive. He did
not view the 5 % false positive rate threshold as an immutable postulate but rather as a
convenient evidence benchmark that could guide scientific decision making [30,31]. “If
P is between 0.1 and 0.9 there is certainly no reason to suspect the hypothesis tested. If
it is below 0.02 it is strongly indicated that the hypothesis fails to account for the whole
of the facts. We shall not often be astray if we draw a conventional line at 0.05 . . .” [32]
Thus, much of our biomedical research progress in the last 80 years has been based on
a metric that is subjective and imperfect, but useful. We propose that we can address
some of these imperfections and better identify important biological results by consid-
ering additional carefully chosen guidelines.
The overall objective of DiCE is to encourage the collection of data in several cat-
egories, since no single category is typically necessary or sufficient to supply compel-
ling evidence of causation. With this method if one category of evidence is
unavailable or biased the direction of future research will not necessarily be deleteri-
ously altered. In addition, this approach depends on interdisciplinary coordination,
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which can build bridges among researchers from disparate fields, improving the speed
and quality of discovery.
Of course, as with any approach to evidence synthesis the efficacy of this method will
depend on the quality of the available prior studies and their annotation as well as the
technology used to access this information. The utility of this strategy will be limited
where relevant information does not exist, is derived from flawed studies, or is difficult
to access. Researchers with expertise in the relevant subject matter and methodologies
should be consulted when the value of a piece of evidence is in question. Furthermore,
Chanock et al. 2007 provides a detailed list of considerations to help guide researchers
when making study quality assessments [1]. These judgments may be particularly im-
portant in the context of low quality omic studies that could provide a poor foundation
for directing further inquiry. Essentially, this approach will be useful where it is
thoughtfully applied. Furthermore, with the advent of modern text-mining methods this
approach can be semi-automated for use in high throughput examination of multiple
findings prior to human interpretation.
Widespread application of DiCE also has the potential to increase the credibility of
biomedical research by appropriately conveying uncertainty to all audiences and in-
creasing likelihood that highly publicized findings will have biological relevance. Re-
viewers and editors may still require a specific level of statistical evidence (e.g. p < 5 ×
10−8), but with the addition of a DiCE score both significant and non-significant p-
values can be better contextualized in terms of their likelihood of having biological rele-
vance in the pathophysiology of interest. Published findings will be as accessible as they
were before DiCE, but bold interpretation, publicity, and translation attempts will be
hard to defend in the context of a low DiCE score. A DiCE score can allow readers to
quickly gauge the corroborating evidence from beyond the paper they are reading, and
a low DiCE score can encourage the lay press to include appropriate caveats in their re-
ports or to wait until the evidence is stronger before reporting. If a preliminary finding
is exciting and diverse evidence has not been collected, a low DiCE score should en-
courage researchers to collect the remaining evidence without delay, and thus the qual-
ity of the finding should be quickly ascertained. Thus DiCE scores can be expected to
have a dynamic and productive interplay with the literature. Overall, this method
should improve the research dissemination process by providing a simple metric for
journals, researchers, the media, and the general public to better vet findings. Further,
by providing a diverse range of evidence, a wider range of domain experts can weigh in
on scientific findings, rather than with the current scenario where most results are re-
ported to and evaluated by a very specific group of domain experts. This should pro-
mote the broad evaluation and sharing of a given set of results, allowing for better
guidance and coordination future research directions.
Logistics: DiCE scores can be quickly added and easily incorporated into any GWAS report
DiCE is designed to provide information that complements standard statistical valid-
ation methods. Thus DiCE can be used to systematically characterize GWAS significant
hits to assess for the likelihood of false positive conclusions and suggest future research
directions. It can also be used to characterize a small number of sub-threshold statis-
tical associations (e.g. those with the 10 smallest sub-threshold p-values) to assess for
the likelihood of false negative conclusions. The utility of DiCE may be expanded
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with the development of semi-automated procedures for calculating DiCE scores.
With semi-automated implementation protocols DiCE could be applied to all nomin-
ally significant GWAS findings to detect possible false negative conclusions in this
larger group.
Why allow for omic analytic strategies that do not adhere to rigid multiple testing
adjustments?
Strict multiple testing correction results in the inefficient use of expensive data. Omics
technologies such as GWAS can produce a list of candidate factors enriched for answers,
but they cannot produce a list of answers. Our traditional omic analytic methods for the
discovery of factors influencing pathology implicitly assume that complex diseases have
simple etiologies (i.e. no covariates or interactions will affect independent validation), and
that observational data is virtually devoid of cryptic bias, confounding, and measurement
error. If we strictly adhere to simplistic models, we will fail to access the substantial
amount of knowledge that is embedded in findings that fail standard validation.
The desire to require extremely small p-values flows, in part, from the laudable aspir-
ation to reduce the number of false positive findings. However, this approach increases
the likelihood of false negative conclusions, the cost of which is not trivial. The require-
ment of very small p-values also reflects the expectation that simple answers will flow
from omic tools. We use significance thresholds that give us a small number of answers
to consider, and squeeze datasets so tightly that only the most extreme findings are
considered valid. Accepted omic results may only be this extreme from a combination
of true effects and chance. To obtain a GWAS significant result, one needs: 1) a large
effect size; 2) a precise effect estimate; or 3) luck. Large effect sizes are uncommon in
complex disease; therefore, we attempt to increase the precision of estimates with large
sample sizes (which may be counterproductive if heterogeneity is increased when add-
ing participants). However, we often depend on the luck of the draw (cf. “winners
curse”) [33,34], when we insist on extreme levels of certainty from a single analysis.
It should also be noted here that the rationale behind multiple testing adjustments
and their use in certain contexts has been exposed to important criticisms in the last
25 years [35]. In 1990 Kenneth Rothman proposed that attempting to reduce the num-
ber of false positive findings with multiple testing adjustments can hinder observation
and impede the advancement of science. “An association that would have been interest-
ing to explore if examined alone can thus be converted to one that is worth much less
attention if judged by the criteria based on [multiple comparison] adjustments. Since
other associations in the set of comparisons may have no bearing on the one in question,
the upshot is that irrelevant information from the data can diminish the informativeness
of an association of possible interest.”
With the advent of omic research designs, and the development of new options for mul-
tiple testing adjustment, Rothmans’s analysis has become even more important, and a
number of authors have extended his comments, including Bender and Lange [36]: “ . . .
in exploratory studies without prespecified hypotheses there is typically no clear structure
in the multiple tests, so an appropriate multiple test adjustment is difficult or even impos-
sible. Hence we prefer that data of exploratory studies are analyzed without multiplicity
adjustment . . . To confirm these results, the corresponding hypotheses have to be tested in
confirmatory studies.”
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Recently, Williams and Haines revisited and extended these lines of thought [8]. They
emphasized that relative importance of type I and type II error is dependent on the
stage of the research, and that requiring both multiple testing correction and independ-
ent validation causes an unacceptable number of meaningful leads to be ignored. If one
is early in the discovery process and has the capacity to gather follow-up evidence then
type II errors should be of greater concern because the type I errors will be corrected
but the type II errors will not be. “We argue that when examining an array of nomin-
ally positive findings, statistical stringency alone does not permit us to determine which
findings are by chance and which are not, and therefore, setting too stringent cutoff for
Type I error criterion for association decreases power to find real associations.”
DiCE further extends these ideas by emphasizing that the processes of validation
should be dependent on diverse evidence, because this better addresses the type I/type
II error problem, as well as other recognized and unrecognized weaknesses of omic
analyses. With this method we have not abandoned our concern for type I error. We
still value the evidence that comes from small p-values and rely on independent con-
firmation, but we now deliberately acknowledge the importance of type II errors and
proactively attempt to reduce them.
To the extent that our approach streamlines the consideration of diverse convergent
evidence, it can speed up the progression from omic findings to interventions.
Comparison of DiCE to existing procedures for knowledge integration
DiCE is a semiformal, dynamic heuristic that reflects the strength of available diverse
convergent evidence, and it is designed to supplement standard statistical validation
procedures. This makes it different from most statistical analytic approaches, but there
are some useful comparisons to be made with other methods. In particular, discussing
Meta-analysis, Inter-Rater Reliability, and Inference Ranking techniques should help to
contextualize the role of DiCE in high throughput genetic research.
In genetic research meta-analysis typically utilizes fixed effect models to integrate in-
formation from multiple observational studies to estimate a single association magni-
tude (and p-value) for a given SNP [37]. Thus, it is most useful when the association
magnitude for a given variable is effectively universal (i.e. not context dependent). In
contrast, DiCE scores integrate available information from observational studies, bio-
logical databases, and experiments to provide a structured assessment of the likelihood
of biological relevance of a given SNP. This is very useful information when the ob-
served association magnitudes vary by context (genetic or environmental background),
or the observational studies share a consistent bias that generates a precise yet inaccur-
ate association magnitude.
The fixed effect meta-analyses typically used in discovery genomics settings obtain a
single omnibus effect estimate by assuming the heterogeneity of effect size is due to
random error [37]. However, we know that context dependent associations and differ-
ential biases can also generate heterogeneity. Thus, this assumption may often be un-
reasonable, and there is a need for discovery approaches that have utility when the
effect size variation is not due to random error. Random effect meta-analyses can better
account for population specific heterogeneity but they still yield one “average” associ-
ation magnitude, and they likely won’t clarify if the heterogeneity is due to context
dependent effect sizes or differential biases. However, DiCE should have utility in these
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settings because the DiCE score is unlikely to be elevated when significant omic find-
ings are driven purely by bias or random error. A high DiCE score in the context of
heterogeneous omic study results suggests that the significant associations may be due
to a true context dependent association rather than random error or differential bias. A
low DiCE score in this setting suggests that random error or differential bias may have
generated the significant associations, or that relevant informatic/experimental evi-
dence has not yet been collected.
Conceptually the DiCE score is similar to an ordinal inter-rater reliability (IRR)
metric [38] in a setting where there are 3 “raters”: omics, informatics, and experiments.
Each “rater” provides an assessment: found any evidence of biological relevance or
found no evidence of biological relevance. More concordant responses result in a
higher DiCE score. Important comparisons can also be made with inference ranking
systems from Environmental Health and high-throughput Toxicology. Because it is not
currently feasible for researchers to thoroughly assess the safety of every chemical that
humans may be exposed to, researchers must prioritize their efforts to identify chemi-
cals likely to pose the greatest risk to public health based on currently available evi-
dence. In this setting, integrating diverse evidence into a rank score helps guide the
direction of future research as well as facilitate science communication and decision
making [39,40]. Thus, diverse evidence based prioritization systems have established
their utility in an analogous high throughput data setting. Furthermore, approaches that
leverage convergent evidence have already shown some utility in guiding genetic ana-
lyses [41-44], and now DiCE expands this concept and provides an accessible protocol
that should facilitate its wider use.
Conclusion: Diversify validation strategies to advance the progress of research
In this paper we present a new method (DiCE) for improving the detection and validation
of relevant biological signals in omic data by proactively considering diverse evidence. This
approach provides a chance to strengthen our validation strategies and advance the progress
of research. We argue that DiCE, when properly implemented, should leverage multidiscip-
linary information to reduce rates of both false positive and false negative conclusions.
Standard validation protocols implicitly assume that there is one truth (i.e. a marginal find-
ing) and it will be discoverable no matter what the contextual background (covariates,
biases, confounding). Furthermore, these validation procedures, when used in isolation, can
lead to incorrect conclusions when there is a consistent bias in the observational studies.
Therefore, many causal factors will go unnoticed and some meaningless “hits” may be over-
interpreted without the development of additional validation approaches, such as DiCE.
The utility of gathering diverse classes of evidence in the context of complex disease re-
search is not a new idea [45], but in current research practice the simplicity and allure of
rigid statistical criteria often overshadows this basic concept. We should not forget that
statistical criteria are very important tools but not substitutes for more complete scientific
investigation and reasoning. Our framework is designed to promote this kind of compre-
hensive scientific reasoning. The recent improvements in observational research tech-
nologies/algorithms, informatics/systems biology resources, and laboratory based disease
models have the potential to greatly advance research efficiency and productivity, if
thoughtfully coordinated. These guidelines should promote the synergy that will allow
these technologies to deliver on their promises.
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Definition of terms as used here
Replication
An attempt to assess the consistency of association by trying to repeat the results in an
independent sample from the original population with the same analytic approach [2].
Validation
An attempt to assess the consistency and generalizability of association by trying to re-
peat the results in an independent sample from a different population using either the
same analytic method or a different approach [2].
Cofactor
A component cause or causal cofactor (e.g. biological factors that physically interact to
generate pathogenic mechanisms). Component causes are factors that are insufficient
to cause disease by themselves but can help cause disease when they occur with other
component causes. For more details see [46].
Covariate
A variable that may impact the estimated association between the variable of primary
interest and the outcome (via confounding, interaction, and etc.) A covariate may have
this impact through causal or non-causal (correlational) relationships. If not properly
considered in the analysis covariates may generate bias in the estimated association be-
tween the variable of primary interest and the outcome. Cofactors are covariates that
may influence estimated associations through causal mechanisms.
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